博雅生物(300294) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was ¥650,690,995.81, a decrease of 0.11% compared to ¥651,435,637.54 in the same period last year[8] - Net profit attributable to shareholders was ¥95,900,464.56, an increase of 7.51% from ¥89,201,436.67 year-on-year[8] - Basic earnings per share increased by 9.52% to ¥0.23 from ¥0.21 in the same period last year[8] - Operating profit increased by 11.32% to RMB 116,061,078.09 year-on-year[26] - Blood products business revenue grew by 18.34% to RMB 242,075,806.13, with a net profit increase of 4.29%[27] - Net profit for the period was ¥99,887,304.66, up from ¥92,274,118.33, indicating a growth of approximately 6.9%[81] - The total profit for the period was ¥122,138,770.20, compared to ¥110,918,703.54 in the previous period, reflecting an increase of about 10.0%[81] Cash Flow - Net cash flow from operating activities was ¥70,048,130.64, a significant improvement from a negative cash flow of -¥82,449,829.13 in the previous year, representing a change of -184.96%[8] - Cash flow from operating activities increased by 184.96% to RMB 70,048,130.64, driven by increased sales receipts[22] - Operating cash inflow for the current period was CNY 657,032,658.71, an increase of 10% compared to CNY 597,297,232.82 in the previous period[89] - Net cash flow from financing activities was CNY 202,991,519.41, compared to a net outflow of CNY -142,192,701.26 in the previous period[95] - The company reported a net cash flow from investment activities of CNY -156,270,685.96, an improvement from CNY -238,469,515.47 in the previous period[92] Assets and Liabilities - Total assets as of March 31, 2020, were ¥5,521,881,351.25, reflecting a growth of 5.04% compared to ¥5,256,690,601.18 at the end of the previous year[8] - Current liabilities rose to ¥1,122,847,401.87 from ¥956,509,297.38, an increase of about 17.39%[66] - Total liabilities increased to ¥1,433,404,751.57, compared to ¥1,268,103,883.65, reflecting a growth of approximately 13.04%[66] - Owner's equity totaled ¥4,088,476,599.68, up from ¥3,988,586,717.53, indicating an increase of about 2.25%[69] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,392[14] - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., held 30.56% of the shares, amounting to 132,421,412 shares[14] Research and Development - Research and development expenses increased by 53.63% to RMB 18,087,809.55, reflecting higher investment in R&D[22] - The company has terminated the blood product R&D center and pilot workshop renovation project due to the establishment of a new R&D center in Beijing, which is expected to reduce management costs and avoid duplicate investments[44] Investments and Acquisitions - The company terminated the acquisition of 48.87% equity in Wuxi Luoyisheng Bio-pharmaceutical Co., Ltd. due to the failure to obtain regulatory approval[35] - The company has invested RMB 36.44 million to acquire a 32% stake in Zhejiang Haikang Biological Products Co., Ltd., using excess funds of RMB 35.94 million for this transaction[46] Operational Updates - As of the end of the reporting period, all twelve plasma collection stations have resumed operations, although daily collection numbers are still subject to local pandemic control measures[31] - The company has actively applied for new plasma collection stations in eligible areas to enhance raw plasma supply capacity[31] - The company aims to actively expand new plasma stations and increase the supply of raw plasma through self-development strategies[44] Other Financial Metrics - The company reported a significant increase in government subsidies, contributing to a 73.62% rise in non-operating income to RMB 13,306,983.59[22] - The company reported a significant reduction in credit impairment losses, decreasing from -¥20,619,476.55 to -¥5,142,577.32[79]